

Recognizing Escalation Triggers in High-Risk CSCC

Clinical features and scenarios that may warrant broader evaluation beyond local management

When Should Clinicians Look Beyond Local Control?

High-risk CSCC can progress despite local surgery and radiation therapy.¹

Certain tumor or patient characteristics should prompt broader evaluation and multidisciplinary coordination.^{2,3}

1

LOCAL MANAGEMENT


Surgery ± radiation completed^{2,4}

2


ESCALATION TRIGGERS

Consider broader evaluation when one or more of the following are present^{*2-7}


Tumor Features



Large tumor size (≥2 cm)



Invasion ≥2 mm or beyond subcutaneous fat



High-risk anatomic locations (head, neck, hands, feet, pretibial, and anogenital areas)




EXPERT INSIGHTS



THE H ZONE IS A HIGH-RISK AREA ON THE FACE. IMAGINE AN H ACROSS THE FACE THAT INCLUDES THE AREA IN FRONT OF THE EARS AND ACROSS THE LIP.



Poor differentiation



Perineural invasion



Recurrent disease




Disease Behavior



Rapid growth



Progressive disease burden




Suspicious nodal findings



Patient Factors



Immunosuppression



Prior RT or chronic inflammation at the tumor site



Significant comorbidities



EXPERT INSIGHTS



PATIENTS WITH CSCC AND IMMUNE-COMPROMISING COMORBIDITIES, SUCH AS CLL OR SOLID ORGAN TRANSPLANTATION, REPRESENT A PARTICULARLY HIGH-RISK POPULATION.

3

NEXT STEPS BEYOND LOCAL MANAGEMENT

Consider the following to guide further evaluation and care^{2-4,6}



Closer Surveillance

Increase frequency of clinical examination and follow-up



Imaging Consideration

Evaluate for regional or distant disease as clinically indicated



Multidisciplinary Discussion

Engage appropriate specialists early for collaborative decision-making



Referral Coordination

Consider referral to medical oncology, radiation oncology, or other specialists as appropriate



Broader Treatment Planning

Evaluate potential role for adjuvant therapy and individualize care



EXPERT INSIGHTS



EVEN WHEN ADJUVANT THERAPY IS MANAGED BY OTHER SPECIALISTS, DERMATOLOGISTS REMAIN CENTRAL TO ONGOING PATIENT CARE, PLAYING A VITAL ROLE IN AE MONITORING AND MANAGEMENT.

Clinical Judgement Matters

Escalation decisions are often driven by cumulative risk. Use clinical judgement and a multidisciplinary approach to guide individualized patient care.

REFERENCES

1. Porceddu SV, et al. *J Clin Oncol*. 2018;36(13):1275-1283.
2. Trager MH, et al. *J Am Acad Dermatol*. 2026;94(3):914-923.
3. Paradelade de la Morena S, et al. *Actas Dermosifiliogr*. 2026;117(6):104612.
4. Alam M, et al. *J Am Acad Dermatol*. 2018;78(3):560-578.
5. Karia PS, et al. *J Clin Oncol*. 2014;32(4):327-334.
6. Rischin D, et al. *N Engl J Med*. 2025;393(8):774-785.
7. Amin MB, et al, eds. *AJCC Cancer Staging Manual*. 8th ed. New York, NY: Springer; 2017.